Teva hopes to develop treatments for chronic conditions using the Watson Health Cloud’s cognitive computing capabilities.
Teva Pharmaceutical Industries Ltd and IBM announced a new partnership on Thursday. The Israeli pharmaceutical giant was selected as the first Foundational Life Sciences Partner for the Watson Health Cloud program, gaining access to its big data capabilities.
IBM’s Watson is the first commercially available cognitive computing platform that can process natural language queries and crunch vast amounts of data. Teva plans to use the global technology platform to design treatments for “unmet and emerging patients” including millions of people who suffer from chronic conditions like asthma, migraine, and pain.
“By building on the Watson Health Cloud, we believe Teva will be in a unique position to put the best information and insights in the hands of physicians, care teams and patients, to empower treatment optimization for individuals and populations across the spectrum of acute and chronic conditions,” said Teva SVP Guy Hadari.
The two firms will also create a joint Teva-IBM Research team that will use big data to model diseases and potential therapeutic treatments.
“Teva’s pioneering digital health vision, reaches across global markets, extensive portfolio of medicines and significant industry experience make them a preferred life science ecosystem partner for the Watson Health Cloud,” said IBM Watson SVP Mike Rhodin.
This article has been extracted from http://www.globes.co.il, please click on this link to read the article in full http://www.globes.co.il/en/article-teva-ibm-partnership-to-seek-big-data-health-solutions-1001068493
Montash is a multi-award winning global technology recruitment business. Specialising in permanent and contract positions across mid-senior appointments across a wide range of industry sectors and IT functions, including: